Participants can access the live conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and referring to the Acceleron ASH 2017 update.
The live webcast can be accessed on the Investors page of the company's website at www.acceleronpharma.com.
A replay of the webcast will be available approximately two hours after the event on the Acceleron website.
Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary program with a Phase 2 trial of sotatercept planned in pulmonary arterial hypertension.
Vice President, Investor Relations and Corporate Communications
Manager, Investor Relations and Corporate Communications
News Provided by Acquire Media